Results 41 to 50 of about 14,566 (186)

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Pilot Study of Behavioral Activation Treatment for Negative Symptoms in Older Adults With Schizophrenia Spectrum Disorder

Psychiatric Research and Clinical Practice, Volume 8, Issue 2, Page 88-95, Summer 2026.
Objective Behavioral activation (BA) is an established treatment for depression in older adults, yet BA has been relatively less examined as a treatment for the negative symptoms (NS) of schizophrenia spectrum disorder (SSD). We here aimed to demonstrate the feasibility and proof‐of‐concept that BA can improve NS and function in older adults with SSD ...
Stephen F. Smagula, Jessica M. Gannon, Fabio Ferrarelli   +2 more
wiley   +1 more source

Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry

Therapeutic Advances in Psychopharmacology, 2020
Background: There is limited data from large naturalistic studies to inform prescribing of long-acting injectable medication (LAIs). Guidance is particularly rare in the case of primary mood disorders.
Emmanuel Stip, Syed Javaid, Jonathan Bayard-Diotte, Karim Abdel Aziz, Danilo Arnone   +4 more
doaj   +1 more source

Altered Brain Tissue Volumes With Valproate Treatment for Schizophrenia

Journal of the Royal Society of New Zealand, Volume 56, Issue 2, April 2026.
Schizophrenia is a debilitating psychiatric condition that affects ≈0.5% of the global population. Some people with schizophrenia do not respond to first‐line antipsychotics and are prescribed clozapine; this is termed treatment‐resistant schizophrenia (TRS).
Thomas Cawood, Olivia K. Harrison, Meghan McIlwain, Robert R. Kydd, Bruce R. Russell   +4 more
wiley   +1 more source

Establishing a dose-response relationship for haloperidol decanoate

, 2005
AIMS AND METHODThe aim of this literature analysis was to establish the range of doses of haloperidol decanoate effective in preventing relapse in schizophrenia.
Taylor, David; id_orcid
core   +1 more source

Improvement of tardive dyskinesia after switching from zuclopenthixol decanoate to paliperidone palmitate: a case report [PDF]

Düşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi, 2014
Long-acting injectable (LAI) antipsychotics are an effective option in schizophrenia that increase treatment adherence in potentially non-compliant patients.
eren yildizhan, filiz ozsoy, berna ozata yildizhan   +2 more
doaj  

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 228-240, January 2026.
Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan, Lynn Miller, Sam Wade, Jenni Ilomäki, Dickson Lukose, Jia Rong, Geoffrey I. Webb   +6 more
wiley   +1 more source

Comparison of Side Effects Between 3‐Monthly and 1‐Monthly Paliperidone Palmitate Formulations in Patients With Schizophrenia

Human Psychopharmacology: Clinical and Experimental, Volume 41, Issue 1, January 2026.
ABSTRACT Background The paliperidone palmitate 3‐month (PP3M) formulation offers an extended dosing interval compared to the 1‐month (PP1M) formulation. However, data on the comparative side effect profiles of PP1M versus PP3M in real‐world settings remain limited.
Erkan Kuru, Ilker Ozdemir, Bengu Yucens, M. Hakan Türkçapar   +3 more
wiley   +1 more source

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis

Neuropsychiatric Disease and Treatment, 2021
Martin Hýža,1,2 Petr Šilhán,1,2 Eva Češková,1,2 Tomáš Skřont,1 Ivana Kacířová,3,4 Romana Uřinovská,3 Milan Grundmann4 1Department of Psychiatry, University Hospital Ostrava, Ostrava ...
Hýža M, Šilhán P, Češková E, Skřont T, Kacířová I, Uřinovská R, Grundmann M   +6 more
doaj  

FAERS‐Based Pharmacovigilance Study on Drug‐Induced Extrapyramidal Disorder: Risk Signals and Mechanistic Insights

Advances in Pharmacological and Pharmaceutical Sciences, Volume 2026, Issue 1, 2026.
Purpose This study aimed to identify high‐risk drugs for drug‐induced extrapyramidal disorder (EPD) and explore their molecular mechanisms by integrating pharmacovigilance analytics with genetic and computational approaches. Methods We performed disproportionality analysis on FAERS data (2004–2024) to detect EPD signals, time‐to‐onset analysis to ...
Hao Wen, Wenfang Xu, Ruiting Wang, Anjali Chauhan   +3 more
wiley   +1 more source